2 weeks Ago By [email protected] (MENAFN)
( MENAFN - GetNews) DelveInsight's, “Acute Ischemic Stroke Pipeline Insight 2024” report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Acute Ischemic Stroke pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type.
It further highlights the inactive pipeline products in this space. Explore our latest breakthroughs in Acute Ischemic Stroke Research. Learn more about our innovative pipeline today! @ Acute Ischemic Stroke Pipeline Outlook Key Takeaways from the Acute Ischemic Stroke Pipeline Report Stay informed about the cutting-edge advancements in Acute Ischemic Stroke treatments.
Download for updates and be a part of the revolution in care @ Acute Ischemic Stroke Clinical Trials Assessment Acute Ischemic Stroke Emerging Drugs Profile Prourokinase recombinant, is an investigational drug being developed by Tasly Pharmaceutical for the treatment of Acute Ischemic Stroke. Recombinant human (rh) Pro-UK, is a novel type of thrombolytic, which preferentially activates plasminogen on the fibrin surface and induces fibrin-selective clot lysis. It has the advantages of more potent efficacy and less adverse reactions in comparison with other thrombolytics.
Advantages of thrombolytic therapy using rhPro-UK for patients with acute myocardial infarction include its reliable curative effect and high safety. Currently, the drug is in the Phase III stage of its development for the treatment of Acute Ischemic Stroke. RNS60 is being developed to provide disease modifying and potentially restorative treatments for neurological diseases.
It activates intracellular signaling pathways to increase mitochondrial biogenesis and function and reduce inflammation. RNS60 safely protects neurons and oligodendrocytes and modulates the activity of immune cells to restore homeostasis. RNS60 has been granted Orphan Drug and Fast Track designations for ALS from the U.
S. Food and Drug Administration. Currently, the drug is in the Phase II stage of its development for the treatment of Acute Ischemic Stroke.
AVLX-144 is a dimeric peptide-like drug candidate for the treatment of AIS, which targets the intracellular scaffolding protein, PSD-95. AVLX-144 is an extensively optimized dimeric PSD-95 inhibitor and a clinical lead candidate for the treatment of acute conditions such as AIS and subarachnoid hemorrhage (SAH). PSD-95 bridges the glutamate receptor subtype - the N-methyl-D-aspartate (NMDA) receptor and neuronal nitric oxide synthase (nNOS) via its two PDZ domains and AVLX-144 binds to both these PDZ domains simultaneously.
The specific design of AVLX-144 provides several key advantages such as exceptionally high affinity to PSD-95, increased stability, and enhanced neuroprotective properties. Currently, the drug is in the Phase I stage of its development for the treatment of Acute Ischemic Stroke. Learn more about Acute Ischemic Stroke Drugs opportunities in our groundbreaking Acute Ischemic Stroke Research and development projects @ Acute Ischemic Stroke Unmet Needs Acute Ischemic Stroke Companies Tasly Pharmaceutical, Revalesio Corporation, Avilex Pharma, GNT Pharma, Biogen, AptaTargets, NC Medical Research, Prolong Pharmaceuticals, Saillant Therapeutics, TargED Biopharmaceuticals and others Acute Ischemic Stroke pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
Acute Ischemic Stroke Products have been categorized under various ROAs such as Acute Ischemic Stroke Products have been categorized under various Molecule types such as Discover the latest advancements in Acute Ischemic Stroke treatment by visiting our website. Stay informed about how we're transforming the future of disease @ Acute Ischemic Stroke Market Drivers and Barriers, and Future Perspectives Scope of the Acute Ischemic Stroke Pipeline Report For a detailed overview of our latest research findings and future plans, read the full details of Acute Ischemic Stroke Pipeline on our website @ Acute Ischemic Stroke Emerging Drugs and Companies Table of Content About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe.
Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. MENAFN05112024003238003268ID1108854752 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article.
If you have any complaints or copyright issues related to this article, kindly contact the provider above..
